Q&A: Lon­za­'s Chris­t­ian Dowdeswell talks HPA­PIs and the Oas­mia deal

The mR­NA boom has been ben­e­fi­cial for CD­MOs, and Lon­za is no dif­fer­ent. It’s up­grad­ed three of its sites — two in Eu­rope and one in New Hamp­shire — since land­ing deals with Mod­er­na to pro­duce the biotech’s Covid-19 vac­cine, and is be­ing con­sid­ered one of the big­wigs that will be re­spon­si­ble for more than half of the world’s drug ca­pac­i­ty by 2025.

And last week, the Swiss drug­mak­er inched clos­er to that goal, when it an­nounced the com­ple­tion of a mas­sive up­grade at a Nan­sha, Chi­na man­u­fac­tur­ing site. The up­grade will ex­pand the com­pa­ny’s abil­i­ty to man­u­fac­ture high­ly po­tent ac­tive phar­ma­ceu­ti­cal in­gre­di­ents, and a deal has al­ready been signed with Oas­mia Phar­ma­ceu­ti­cals to make its ovar­i­an can­cer drug can­di­date. That will start lat­er this month.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.